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A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by
Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%.
Ceftaroline nonsusceptibility (MIC,>1.0g/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%,
58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P< 0.0001). Nonsus-
ceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.
Ceftaroline, an oxyimino-cephalosporin active against methi-cillin-resistant Staphylococcus aureus (MRSA) due to en-
hanced affinity for penicillin binding protein (PBP) 2a, was ap-
proved for use in Australia in 2013 for the treatment of complicated
skin and soft tissue infections (SSTIs) and community-acquired
bacterial pneumonia (CABP), following approvals for the same
indications in the United States in 2010 and Europe in 2012. S.
aureus MIC breakpoints have been set by the Clinical and Labo-
ratory Standards Institute (CLSI) (1) and the European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) (2). Both
report a susceptibility MIC of1.0g/ml, although they differ in
the resistance designation (CLSI, resistant MIC of 4.0 g/ml;
EUCAST, resistant MIC of1.0g/ml). Resistance appears to be
associated with decreased PBP2a binding affinity (3–7) and het-
eroresistance (8). Reports have largely demonstrated minimal re-
sistance, although geographical variation has been noted (4, 7,
9–33) (Table 1). More recently, in hospital-associated MRSA
(HA-MRSA) isolates from China, ceftaroline nonsusceptibility
was 33.5% (84/251); most (95.2%) belonged to clonal complex
(CC) 8, and sequence type (ST) 239-III was the majority (9). Sim-
ilarly, ceftaroline nonsusceptible MRSA isolates from Eastern
Australia were all ST239-III clones (10). A German study also
demonstrated increased ceftaroline MIC50 and MIC90 values for
isolates of clonal lineages ST228 and ST239 (7).
Nonduplicate, consecutive clinical MRSA isolates were tested
from patients treated at the Alfred Hospital, a tertiary-care met-
ropolitan hospital inMelbourne, Australia, over two time periods:
July toDecember 2010 andAugust toNovember 2013. Ceftaroline
was not in use clinically before 2014. Isolates from 2010 and 2013
were identified using Vitek 2 and Vitek MS (bioMérieux), respec-
tively. Susceptibility testing was performed using the Vitek 2 Gram-
positive susceptibility card (AST-P612), applying EUCAST break-
points. The multidrug resistant phenotype was defined as
resistance to 3 non--lactam antibiotics, including ciprofloxa-
cin, erythromycin/clindamycin, gentamicin, co-trimoxazole, and
tetracycline. All isolates were assessed for ceftaroline and vanco-
mycin susceptibility by Etest (bioMérieux). Isolates from 2010
that had been frozen were thawed and subcultured twice before
testing. Isolates from 2013 were collected and tested in real time.
Ceftaroline Etests were set up on Mueller-Hinton agar (Becton
Dickinson BBL 211438), incubated, and read per manufacturer’s
guidelines. Ceftaroline nonsusceptibility was defined as a MIC of
1.0 g/ml. Confirmatory broth microdilution (BMD) was not
available. Typing was performed by a high-resolution melting-
based method, giving inferred CCs (34).
A total of 421 nonduplicate MRSA isolates were identified for
testing. Of the total, 270 isolates were from 2010, and 151 isolates
were from 2013. SSTIs accounted for the majority (70.3%) of
specimens. Strains with amultidrug-resistant phenotypemade up
40.9% of the isolates, although this proportion declined over the
two time periods, from 47.0% (127/270) in 2010 to 29.8% (24/
151) in 2013. CC239, the dominant HA-MRSA strain found in
Australia, and often multidrug resistant (11), was the most com-
monly identified clonal complex, accounting for 33.5% of all iso-
lates. This proportion also decreased between the two time peri-
ods, from 41.5% (112/270) in 2010 to 19.2% (29/151) in 2013.
CC22 and CC45 were the next most commonly identified clonal
complexes, found in 28.5% and 11.4%, respectively. The propor-
tion of CC22 isolates increased from 26.7% (72/270) in 2010 to
31.8% (48/151) in 2013. Among all MRSA isolates, the vancomy-
cin MIC50 and MIC90 were 1.5 g/ml. Reduced vancomycin sus-
ceptibility (i.e., vancomycin MIC, 1.0 g/ml) was most com-
mon in isolates with a multidrug-resistant phenotype (84.9%,
146/172) and in CC239 isolates (83.7%, 118/141) compared with
those that had a non-multidrug-resistant phenotype (32.9%, 82/
249) or another CC type (39.3%, 110/280).
Overall, the ceftaroline MIC50 and MIC90 values were 0.75
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g/ml and 1.5g/ml, respectively, with a nonsusceptibility rate of
16.9% (71/421). The majority of ceftaroline-nonsusceptible iso-
lates had a multidrug-resistant phenotype (85.9%, 61/71), were
typed as CC239 (81.7%, 58/71) and had a vancomycin MIC of
1.0 g/ml (76.1%, 54/71). All ceftaroline-nonsusceptible iso-
lates hadMICs that were either 1.5g/ml or 2.0g/ml, represent-
ing the upper tail of a unimodal distribution, and were character-
ized as resistant by EUCAST criteria and intermediate by CLSI
(Fig. 1). A two-sample test of proportions demonstrated that cef-
taroline nonsusceptibility was significantly higher in CC239
MRSA isolates than in non-CC239 isolates (58/141 [41.1%] versus
13/280 [4.6%]; P 0.0001). Similarly, ceftaroline nonsusceptibil-
ity in multidrug-resistant MRSA isolates was significantly higher
than in non-multidrug-resistant isolates (61/172 [35.5%] versus
10/249 [4.0%]; P 0.0001).
MIC gradient strip testing and disc diffusion remain the most
common ways for clinical laboratories to test ceftaroline suscep-
tibility in the absence of automatedmethods andwith the imprac-
ticalities of BMD (35). Ceftaroline gradient strip tests have been
reported to underestimate (7), overestimate (12), and demon-
strate reasonably good MIC correlation with BMD (10). Liver-
more et al. reported that discrimination between MICs of 1.0 and
2.0 g/ml by Etest, compared with agar dilution, was poor (36).
Despite this, and despite differences in clinical breakpoints set by
CLSI (1) and EUCAST (2), an Etest ceftaroline MIC of 1.0 g/ml
remains an important and conservative breakpoint for the labo-
ratory to report susceptibility.
The pharmacokinetic and pharmacodynamic index that best
correlates with ceftaroline efficacy is the percentage of time during
the dosing interval that free-drug concentrations remain above
theMIC of the infecting organism (f%TMIC). In a Staphylococcus
aureus neutropenic murine thigh model, the mean  standard
TABLE 1 Published reports of ceftaroline susceptibility in MRSA isolates
Time period Region No. isolates Source MIC50 MIC90 % susceptible
a Reference
1997–2008 Australia 103 Blood 0.5 1.0 100 12
1.0 1.0 100b
2008 United States 2,254 SSTIc 1.0 1.0 94.8 13
Europe 734 1.0 2.0 82.6
2008–2009 United States 215 RESPd 1.0 1.0 94.4 14
Europe 60 1.0 2.0 81.7
2008–2010 United States 4,453 Various 1.0 1.0 96.1 15
2008–2011 United States 9,875 Various 0.5 1.0 97.1 16
2009 United States 2,247 Various 0.5 1.0 98.0 17
2009 Canada 74 CA-MRSAe Various 0.5 0.5 100 18
151 HA-MRSAf 1.0 1.0 100
2009–2011 United States 532 RESP 0.5 1.0 96.2 19
2009–2011 United States 1,492 SSTI 0.5 1.0 99.1 20
2009–2013 United States 12,514 Various 0.5 1.0 97.6 21
2009–2013 United States 2,013 Blood 0.5 1.0 95.4 22
2010 United States 1,072 Various 0.5 1.0 98.4 23
2010 Europe 331 SSTI 1.0 2.0 88.8 24
2010 South Africa and Asia Pacific 211 SSTI and RESP 1.0 2.0 80.6 25
2010–2011g United States 2,143 Various 0.5 1.0 96.8 26
2010–2012g United States 4,333 SSTI 0.5 1.0 98.9 27
2011 Latin America 409h Various 1.0 2.0 61.6 28
2011 Australia 713 Various 0.75 1.0 98.2i 11
2011 United States 2,093 Various 0.5 1.0 98.9 29
2011 China 251 HA-MRSA SSTI 1.0 2.0 66.5 9
2012 Global 4,324 Various 1.0 2.0 85.2 4
2012 Germany 133 Various 1.0 1.5 63.9j 7
0.5 0.75 96.2i
2012–2013 U.K. 531 SSTI 1.0 1.0 95.3k 30
2012–2013 France 67 SSTI 0.5 1.0 97.0 31
2013 Australia 100 Various 0.5 2.0 85.0 10
1.0 2.0 85.0i
2013 United States 2,642 SSTI 1.0 1.0 98.8 32
2014 India 50 Various 0.5 1.0 96.0i 33
a Isolates were tested for susceptibility to ceftaroline by reference broth microdilution methods, as described by CLSI M07-A9, unless otherwise indicated.
b Suceptibility testing by MIC evaluator (MICE) strips (Oxoid).
c SSTI, skin and soft tissue infection.
d RESP, respiratory.
e CA-MRSA, community-associated MRSA.
f HA-MRSA, health care-associated MRSA.
g Study drug was ceftaroline-avibactam.
h Includes isolates from Chile, of which 83.9% had a ceftaroline MIC of 2.0 g/ml.
i Suceptibility testing by Etest (bioMérieux).
j Broth microdilution methods, as described by EUCAST.
k Broth microdilution methods, as described by BSAC (British Society for Antimicrobial Chemotherapy).
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deviation f%TMIC required for bacterial stasis, 1-log10 kill, and
2-log10 kill was 26  8, 33  9, and 45  13, respectively. Less
killing was observed with more widely spaced dosing intervals (12
h and 24 h) (37). Suggestions that ceftaroline susceptibility test
interpretive criteria could be as high as a MIC of 2.0 g/ml (4,
38) are based on achieving an f%TMIC target of 26%, reflecting
bacterial stasis, and would be considered the minimum value re-
quired when uncomplicated infections in patients with an intact
immune system are being treated (39). At a MIC of 2.0 g/ml,
standard dosing of ceftaroline with 600 mg twice daily demon-
strated lower target attainments, aiming for 1- or 2-log10 kill
(74.5% and 28.8%, respectively, in simulated patients with nor-
mal renal function, applying f%TMIC of 36% and 51% for a 1-
and 2-log10 kill, respectively) (38). Monte Carlo simulation with
FIG 1 Ceftaroline MIC distributions in relation to antibiotic susceptibility phenotype and clonal complex (CC). Dark shaded area represents ceftaroline
nonsusceptible MIC range. CC22, clonal complex 22 strain; CC239, clonal complex 239 strain; mMRSA, multidrug-resistant MRSA phenotype; nmMRSA,
non-multidrug-resistant MRSA phenotype.
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ceftaroline administered 600mg every 8 hours as a 2-h infusion in
patients with normal renal function demonstrated a higher prob-
ability of treatment success (from 72% in CABP and 79% in SSTI
to99% in both), and the every-8-hour schedulemay represent a
better option than standard dosing, especially when targeting
MRSA (40). In practice, off-label dosing has been commonly re-
ported for serious infections (e.g., bacteremia, endocarditis,
MRSA pneumonia) with good clinical outcomes, although such
dosing risks higher toxicity rates (41).
Ceftaroline resistance amongMRSA isolates fromMelbourne,
Australia, especially the isolates with amultidrug-resistant pheno-
type and the CC239 strain, is significant and would preclude its
empirical use prior to dedicated susceptibility testing. Empirical
usage in other settings should be determined at an individual in-
stitutional level. Ceftaroline nonsusceptibility has been identified
prior to the clinical use of the drug and, therefore, does not rep-
resent the emergence of resistance. Despite the limitations of this
study, which might be biased toward hospital-specific clones, or
whichmight represent the known laboratory issues of the gradient
strip susceptibility test with the lack of confirmatory BMD testing,
our findings linking ceftaroline resistance to a multidrug resis-
tance phenotype and to CC239 are supported by other recently
published studies (4, 9, 10). Our results may also represent
changes in resistance over time, highlighting the importance of
monitoring MRSA molecular epidemiology in order to under-
stand the underlying genetic background to nonsusceptibility and
the dynamic relationship that is seen between the pathogen and
the drug. In regions where CC239 contributes to a large propor-
tion ofMRSA, caution should be exercised in using ceftaroline for
suspected or knownMRSA infections. Although the association of
CC239 and the multidrug-resistant phenotype are inherently
linked, the clinical appreciation at the time of culture result, that a
multidrug-resistantMRSA isolate has a higher background rate of
ceftaroline nonsusceptibility, is an important one. Further studies
are required on the clinical efficacy and safety of using more in-
tensive ceftaroline dosing regimens in such settings.
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